Lactobacillus rhamnosus HN001 facilitates the efficacy of dual PI3K/mTOR inhibition prolonging cardiac transplant survival and enhancing antitumor effect.
- 2024-05-02
- Microbiology spectrum 12(5)
- PubMed: 38564670
- DOI: 10.1128/spectrum.01839-23
Study Design
- Population
- primary liver cancer model mice with cardiac allografts
- Methods
- We established a mouse orthotopic liver tumor model and conducted allogeneic heterotopic heart transplantation. We administered a combination therapy of phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) dual inhibitor BEZ235 and Lactobacillus rhamnosus HN001.
- Animal Study
Solid organ transplantation is a crucial treatment for patients who have reached the end stage of heart, lung, kidney, or liver failure. However, the likelihood of developing cancer post-transplantation increases. Additionally, primary malignant tumors remain a major obstacle to the long-term survival of transplanted organs. Therefore, it is essential to investigate effective therapies that can boost the immune system's ability to combat cancer and prevent allograft rejection. We established a mouse orthotopic liver tumor model and conducted allogeneic heterotopic heart transplantation. Various treatments were administered, and survival curves were generated using the Kaplan-Meier method. We also collected graft samples and measured inflammatory cytokine levels in the serum using an inflammatory array. The specificity of the histochemical techniques was tested by staining sections. We administered a combination therapy of phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) dual inhibitor BEZ235 and Lactobacillus rhamnosus HN001 to primary liver cancer model mice with cardiac allografts. Consistent with our prior findings, L. rhamnosus HN001 alleviated the intestinal flora imbalance caused by BEZ235. Our previous research confirmed that the combination of BEZ235 and L. rhamnosus HN001 significantly prolonged cardiac transplant survival.
Importance
We observed that the combination of phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) dual inhibitor BEZ235 and Lactobacillus rhamnosus HN001 notably prolonged cardiac transplant survival while also inhibiting the progression of primary liver cancer. The combination therapy was efficacious in treating antitumor immunity and allograft rejection, as demonstrated by the efficacy results. We also found that this phenomenon was accompanied by the regulation of inflammatory IL-6 expression. Our study presents a novel and effective therapeutic approach to address antitumor immunity and prevent allograft rejection.Research Insights
| Supplement | Dose | Health Outcome | Effect Type | Effect Size | Source |
|---|---|---|---|---|---|
| Lactobacillus rhamnosus HN001 | — | Enhanced Antitumor Immune Response | Beneficial | Moderate | View sourceThe combination therapy was efficacious in treating antitumor immunity and allograft rejection |
| Lactobacillus rhamnosus HN001 | — | Prolonged Cardiac Allograft Survival | Beneficial | Large | View sourcethe combination of BEZ235 and Lactobacillus rhamnosus HN001 significantly prolonged cardiac transplant survival |
| Lactobacillus rhamnosus HN001 | — | Reduced Allograft Rejection | Beneficial | Moderate | View sourceThe combination therapy was efficacious in treating antitumor immunity and allograft rejection |
| Lactobacillus rhamnosus HN001 | — | Reduced Cancer Progression | Beneficial | Large | View sourcethe combination of phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) dual inhibitor BEZ235 and Lactobacillus rhamnosus HN001 notably prolonged cardiac transplant survival while also inhibiting the progression of primary liver cancer |